

U.S. MARKET FOR THERAPEUTIC RADIOPHARMACEUTICALS

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
1.0	MARKET STATUS, TRENDS AND FORECASTS	1-1
1.1	INTRODUCTION AND OVERVIEW	1-1
1.1.1	Diagnostic-Therapeutic Pairs of Radiopharmaceuticals	1-3
1.1.2	New Targeted Therapy Agents	1-4
1.1.3	Radiotherapeutic Pipeline Products	1-4
1.1.4	Major Progress in International Cooperation	1-8
1.1.5	Russian-American Cancer Alliance	1-9
1.1.6	Relationships with Non-Members of the Alliance	1-10
1.1.7	New Technology Opportunities	1-11
1.1.8	Increased Use of Alpha Emitters	1-12
1.1.9	Importance of Patient Specific Dosimetry	1-14
1.2	THERAPEUTIC PRODUCT SALES AND MARKET FORECASTS	1-16
1.2.1	Sales Summary by Procedure Category and Product Type	1-16
1.2.2	Price Per Dose Assumptions	1-26
1.2.3	Lymphoma Therapy	1-29
1.3	OTHER SOFT TUMORS APPLICATIONS	1-33
1.3.1	Multiple Myeloma and Bone Cancer	1-33
1.3.2	Endocrine Cancer	1-35

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
1.4	PRODUCTS FOR TREATING SOLID TUMORS	1-38
1.4.1	Lung Cancer Therapy	1-40
1.4.2	Prostate Cancer Therapy	1-45
1.4.3	Breast Cancer Therapy	1-45
1.4.4	Colon Cancer Therapy	1-46
1.4.5	Pancreatic Cancer and Liver Cancer Therapy	1-47
1.4.6	Malignant Melanoma Therapy	1-50
1.4.7	Other Solid Tumors	1-53
1.5	BONE PAIN PALLIATION	1-54
1.5.1	Bone Palliation Product Mix	1-54
1.5.2	Sales Forecasts	1-55
2.0	ANALYSIS OF PROCEDURE VOLUME	2-1
2.1	INTRODUCTION AND OVERVIEW	2-1
2.2	TARGETED RADIOTHERAPY PROCEDURES	2-3
2.3	ANALYSIS OF DATA SOURCES AND METHODOLOGY	2-4
2.3.1	Sources of Procedure Data	2-5
2.3.2	Advantages and Limitations of Available Data Bases	2-6
2.3.2.1	Advantages of Using Existing Data Bases	2-6
2.3.2.1	Limitations of Some of the Available Data Bases	2-7
2.3.3	CMS Medicare Data	2-7
2.3.4	Impact of Reimbursement on Procedure Coding	2-8

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
3.0	RADIOPHARMACEUTICAL PRODUCTS AND TECHNOLOGY	3-1
3.1	TYPES OF RADIOPHARMACEUTICAL PRODUCTS	3-1
3.2	FUNCTIONAL CHARACTERISTICS	3-5
3.2.1	Radiopharmaceutical Selection	3-6
3.3	RADIOISOTOPE PRODUCTION METHODS	3-9
3.3.1	Nuclear Reactors	3-11
3.3.2	Accelerators	3-14
3.3.3	Radionuclide Generators	3-15
3.4	RADIOPHARMACEUTICAL PREPARATION	3-16
3.4.1	Commercial Radiopharmacies	3-17
3.4.2	New Radiopharmaceuticals	3-18
4.0	CURRENT DEVELOPMENTS AND EMERGING TECHNOLOGY	4-1
4.1	INTRODUCTION AND OVERVIEW	4-1
4.1.1	Treating Lymphoma with Radioimmunotherapy	4-2
4.1.2	Growing Prospects for Therapeutic Antibodies	4-2
4.2	CHARACTERISTICS OF THERAPEUTIC RADIOPHARMACEUTICALS	4-3
4.3	TREATMENTS FOR NON-HODGKINS LYMPHOMA	4-4
4.3.1	Iodine-131 vs. Yttrium-90 Trade-Offs	4-6
4.3.2	Calculating the Clearance Rate	4-7
4.3.3	Toxicity Issues	4-9
4.3.4	Product Stability and Effectiveness	4-10
4.3.5	Y-90 Epratuzumab (Immunomedics)	4-10

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
4.4	NEW ANTIBODY PSMA PRODUCTS FOR PROSTATE CANCER	4-11
4.4.1	Trade-offs Between Lutetium-177 and Yttrium-90	4-12
4.4.2	Realistic Options in Treating the Prostate Cancer Patient	4-12
4.4.3	Unique Aspect of Prostate Cancer Tumors	4-13
4.4.4	Advantages and Limitations of the PSA Test	4-14
4.4.5	Some Advantages of Lutetium-177	4-14
4.4.6	Use of Multiple Drugs and Modalities	4-15
4.4.7	Cytogen's PSMA Therapeutic Antibody	4-17
4.4.8	Agreement with Dow Chemical	4-18
4.5	NEW ANTIBODY DEVELOPMENTS BY IMMUNOMEDICS	4-18
4.5.1	Bispecific Antibodies And Pretargeting	4-18
4.5.2	Humanized PAM4 Antibody for Pancreatic Cancer	4-19
4.6	COTARA TUMOR NECROSIS THERAPY (TNT)	4-20
4.6.1	Iodine-131 Cotara for Brain Tumor Therapy	4-21
4.6.2	Cotara TNT for Lung Cancer Approved in China	4-22
4.7	TARGETING OF GRP RECEPTORS WITH AGONISTS	4-23
4.7.1	Bombesin Agonists and Subtypes	4-23
4.7.2	Tailoring Bombesin to Various Receptors	4-24
4.8	SKELETAL TARGETED RADIATION	4-25
4.8.1	Holmium-166 DOTMP for Bone Marrow Ablation	4-25
4.8.2	Other Dow Developments	4-26
4.9	OCTREOTIDE AND OCTREOTATE FOR ENDOCRINE TUMORS	4-27

TABLE OF CONTENTS

<u>Section</u>	<u>Page</u>
4.10 TARGETING VASCULAR BEDS OF CANCERS	4-27
4.10.1 Endothelia Cell Behavior	4-28
4.10.2 Polymer Drug Delivery Systems	4-29
4.10.3 Enhanced Retention Permeability	4-30
4.10.4 Alpha Emitters	4-31
4.11 TARGETED ALPHA THERAPY WITH AN IN VIVO GENERATOR	4-33
4.11.1 Application in Disseminated Melanoma	4-34
4.11.2 Advantages of Alpha Particles in Melanoma Therapy	4-35
4.12 CONSIDERATIONS IN SELECTING THERAPEUTIC ISOTOPES	4-35
4.12.1 Lanthanide Series of Isotopes	4-36
4.12.2 Product Characteristics	4-37
4.12.3 Alpha Emitters	4-37
4.13 CANCER RETENTION OF PHOSPHOLIPID ETHER ANALOGS	4-38
4.13.1 Mechanism of Action	4-38
4.13.2 Phospholipid Ether Analogs	4-39
4.13.3 Design and Testing of PLE Analogs	4-40
4.13.4 Cellectar's Lead Compound I-125-NM404	4-41
4.13.5 Targeting Non-Small Cell Lung Cancer	4-41
4.13.6 Use of PLE Technology in Diagnostic Imaging	4-42
5.0 END-USER ANALYSIS	5-1
5.1 OVERVIEW OF THE USER ENVIRONMENT	5-1
5.1.1 Organization of Nuclear Medicine Departments	5-2

TABLE OF CONTENTS

<u>Section</u>		<u>Page</u>
5.2	ALLOCATION OF HOSPITAL NUCLEAR MEDICINE EQUIPMENT	5-3
5.3	COMPARATIVE UTILIZATION PARAMETERS	5-4
5.4	DISTRIBUTION OF IMAGING PROCEDURES	5-7
5.4.1	Relative Diagnostic Activity	5-7
5.4.2	Relative Procedure Volume	5-10
5.4.3	Imaging Activity Index	5-11
5.4.4	Distribution of Nuclear Studies in Hospitals & Clinics	5-11
5.5	THE IN-HOSPITAL HOT LAB VS. COMMERCIAL PHARMACIES	5-13
5.5.1	Unit-Dose Packaging	5-14
5.5.2	Pricing Practices	5-15
5.5.3	Other Services	5-16
5.6	NONHOSPITAL END-USERS	5-17
5.7	ISSUES OF BOARD CERTIFICATION	5-18
6.0	COMPANY PROFILES	6-1
6.1	INTRODUCTION	6-1
6.2	ALGETA	6-3
6.3	ALPHAMED INC.	6-5
6.4	ANTISOMA LTD. (UK)	6-7
6.5	BERLEX LABORATORIES	6-10
6.6	BIOGEN IDEC INC.	6-14
6.7	BIO-NUCLEONICS, INC.	6-16
6.8	BOSTON LIFE SCIENCES	6-16

TABLE OF CONTENTS6-

<u>Section</u>	<u>Page</u>
6.9 BRACCO DIAGNOSTICS	6-19
6.10 BRISTOL MYERS SQUIBB IMAGING	6-21
6.11 CARDINAL HEALTH	6-24
6.12 CELLECTAR, LLC	6-26
6.13 CIS BIO-INTERNATIONAL	6-29
6.14 CYTYC CORPORATION (PROXIMA THERAPEUTICS)	6-31
6.15 CYTOGEN CORPORATION	6-34
6.16 DOW CHEMICAL CO.	6-38
6.17 DRAXIMAGE, INC.	6-40
6.18 GE HEALTHCARE DIAGNOSTICS	6-42
6.19 GLAXO SMITHKLINE CORPORATION	6-47
6.20 IMMUNOMEDICS, INC.	6-48
6.21 LYNANTECH INC.	6-51
6.22 MALLINCKRODT INC. (TYCO HEALTHCARE)	6-54
6.23 MDS NORDION	6-57
6.24 MILLENIUM PHARMACEUTICALS	6-60
6.25 MOLECULAR INSIGHT PHARMACEUTICALS INC.	6-63
6.26 PALATIN TECHNOLOGIES INC.	6-66
6.27 PEREGRINE PHARMACEUTICALS INC.	6-68
6.28 SIRTEX MEDICAL LTD.	6-71
6.29 THERAGENICS CORPORATION	6-76
APPENDIX A – LIST OF MANUFACTURERS OF RADIOPHARMACEUTICALS	A-1

**U.S. MARKET FOR
THERAPEUTIC RADIOPHARMACEUTICALS**

LIST OF EXHIBITS

<u>Exhibit</u>	<u>Page</u>	
1-1	THERAPEUTIC ANTIBODIES APPROVED TO DATE	1-5
1-2	THERAPEUTIC PIPELINE PRODUCTS	1-7
1-3	HISTORIC AND FORECAST PROCEDURE VOLUME AND SALES OF THERAPEUTIC RADIOPHARMACEUTICALS FROM 2002-2012	1-17
1-4	2005 THERAPEUTIC RADIOPHARMACEUTICAL SALES SUMMARY BY PROCEDURE CATEGORY AND PRODUCT TYPE	1-18
1-5	2008 THERAPEUTIC RADIOPHARMACEUTICAL SALES SUMMARY BY PROCEDURE CATEGORY AND PRODUCT TYPE	1-19
1-6	2012 THERAPEUTIC RADIOPHARMACEUTICAL SALES SUMMARY BY PROCEDURE CATEGORY AND PRODUCT TYPE	1-22
1-7	HISTORIC AND FORECAST SALES OF THERAPEUTIC RADIO-PHARMACEUTICALS BY PRODUCT CATEGORY FROM 2002-2012	1-25
1-8	HISTORIC AND FORECAST PROCEDURE GROWTH OF THERAPEUTIC RADIOPHARMACEUTICALS BY PRODCROUP FROM 2002-2012	1-27
1-9	HISTORIC AND FORECAST SALES GROWTH OF LYMPHOMA AGENTS BY MANUFACTURER AND PRODUCT TYPE FROM 2002-2012	1-30
1-10	HISTORIC AND FORECAST GROWTH OF LYMPHOMA RADIO-THERAPY PROCEDURES BY MANUFACTURER AND PRODUCT TYPE FROM 2002-2012	1-31
1-11	FORECAST SALES OF NEW THERAPEUTIC RADIOPHARMA-CEUTICALS FOR MYELOMA, BONE CANCER AND ENDOCRINE TUMORS FROM 2008-2012	1-36
1-12	FORECAST GROWTH OF NEW RADIOPHARMACEUTICAL PROCEDURES FOR MYELOMA, BONE CANCER AND ENDOCRINE TUMORS FROM 2008-2012	1-37
1-13	FORECAST SALES OF NEW THERAPEUTIC RADIOPHARMA-CEUTICALS FOR TREATING SOLID TUMORS BY DISEASE TYPE FROM 2008-2012	1-39

LIST OF EXHIBITS

<u>Exhibit</u>	<u>Page</u>	
1-14	FORECAST PROCEDURE VOLUME FOR NEW RADIOPHARMACEUTICALS FOR TREATING SOLID TUMORS BY DISEASE TYPE FROM 2008-2012	1-41
1-15	FORECAST SALES OF NEW RADIOPHARMACEUTICALS FOR LUNG CANCER, PROSTATE CANCER AND BREAST CANCER BY PRODUCT FROM 2008-2012	1-43
1-16	FORECAST NEW PROCEDURE GROWTH FOR FOR LUNG CANCER, PROSTATE CANCER AND BREAST CANCER FROM 2008-2012	1-44
1-17	FORECAST SALES OF RADIOPHARMACEUTICALS FOR, COLON CANCER PANCREATIC CANCER AND LIVER CANCER BY PRODUCT FROM 2008-2012	1-48
1-18	FORECAST GROWTH OF NEW PROCEDURES FOR COLON CANCER, PANCREATIC CANCER AND LIVER CANCER BY PRODUCT FROM 2008-2012	1-49
1-19	FORECAST SALES OF NEW RADIOPHARMACEUTICALS FOR MELANOMA, BRAIN CANCER AND OTHER SOLID TUMORS BY PRODUCT FROM 2008-2012	1-51
1-20	FORECAST PROCEDURE GROWTH FOR NEW RADIOPHARMACEUTICALS FOR MELANOMA, BRAIN CANCER AND OTHER TUMORS FROM 2008-2012	1-52
1-21	HISTORIC AND FORECAST SALES GROWTH OF BONE PAIN PALLIATION RADIOTHERAPY AGENTS BY PRODUCT TYPE FROM 2002-2012	1-56
2-1	GROWTH OF RADIOTHERAPY PROCEDURE VOLUME FROM 2005-2012	2-4
3-1	DIAGNOSTIC AND THERAPEUTIC ISOTOPES	3-4
5-1	COMPARATIVE ALLOCATION OF DIAGNOSTIC FACILITIES BY HOSPITAL BED SIZE IN 2005	5-5
5-2	COMPARATIVE UTILIZATION PARAMETERS FOR DIFFERENT IMAGING MODALITIES IN 2005	5-6

LIST OF EXHIBITS

<u>Exhibit</u>		<u>Page</u>
5-3	DISTRIBUTION OF HOSPITAL DIAGNOSTIC IMAGING PROCEDURES IN THE U.S. BY HOSPITAL BED SIZE IN 2005	5-8
5-4	RELATIVE PROCEDURE VOLUME FOR DIFFERENT IMAGING MODALITIES, PERCENTAGE RELATIONSHIP BY HOSPITAL BED SIZE IN 2005	5-9
5-5	RELATIVE ACTIVITY INDEX AMONG DIFFERENT IMAGING MODALITIES, PROCEDURES PER BED PER YEAR BY HOSPITAL BED SIZE IN 2005	5-11